Welcome to LookChem.com Sign In|Join Free

CAS

  • or

203866-21-1

Post Buying Request

203866-21-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 1,2-Pyrrolidinedicarboxylicacid, 4,4-difluoro-, 1-(9H-fluoren-9-ylmethyl) ester, (2S)-

    Cas No: 203866-21-1

  • No Data

  • No Data

  • No Data

  • yuyongmei
  • Contact Supplier

203866-21-1 Usage

Description

(2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid is a chemical compound with a molecular formula C18H19F2NO4. It is a derivative of pyrrolidine-2-carboxylic acid, featuring a fluorine substitution at the 4th position of the pyrrolidine ring. (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid is characterized by the presence of the Fmoc (9-fluorenylmethyloxycarbonyl) protecting group, which is instrumental in peptide chemistry for its selective deprotection capabilities under mild conditions. It serves as a crucial building block in the synthesis of peptide and protein-based pharmaceuticals, playing a significant role in medicinal and pharmaceutical research.

Uses

Used in Pharmaceutical Synthesis:
(2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid is utilized as a key building block for the synthesis of peptide and protein-based pharmaceuticals. Its incorporation into these biologically active molecules allows for the development of new drugs with potential therapeutic applications.
Used in Solid-Phase Peptide Synthesis:
In the field of solid-phase peptide synthesis, (2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid is employed as a component that protects the amine group in the peptide chain. This protection is vital for preventing unwanted side reactions during the synthesis process, thereby ensuring the production of the desired peptide sequence.
Used in Medicinal Research:
(2S)-Fmoc-4,4-difluoro-pyrrolidine-2-carboxylic acid is also used in medicinal research as a versatile tool for the exploration of novel drug candidates. Its unique structure and the ability to selectively deprotect the amine group make it an attractive candidate for the design and synthesis of new pharmaceutical agents.

Check Digit Verification of cas no

The CAS Registry Mumber 203866-21-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,3,8,6 and 6 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 203866-21:
(8*2)+(7*0)+(6*3)+(5*8)+(4*6)+(3*6)+(2*2)+(1*1)=121
121 % 10 = 1
So 203866-21-1 is a valid CAS Registry Number.

203866-21-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name (2S)-1-(9H-fluoren-9-ylmethoxycarbonyl)-4,4-difluoropyrrolidine-2-carboxylic acid

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:203866-21-1 SDS

203866-21-1Relevant articles and documents

Inhibitors of caspases

-

, (2008/06/13)

The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1β converting enzyme (“ICE”) inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting caspase activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-γ inducing factor-(IGIF), or interferon-γ-(“IFN-γ”) mediated diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases. This invention also relates to methods for inhibiting caspase activity and decreasing IGIF production and IFN-γ production and methods for treating interleukin-1, apoptosis-, and interferon-γ-mediated diseases using the compounds and compositions of this invention. This invention also relates to methods of preparing the compounds of this invention.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 203866-21-1